New Era in Treatment of Hepatitis C
An agreement on transfer of manufacture of innovative highly effective drug for treatment of chronic hepatitis C daclatasvir has been signed between Bristol Mayers Squibb and State Corporation R-Pharm.
In contrast to interferon therapy, the sole hepatitis C treatment that has been available until recently, the new drugs exert direct antiviral effects in viral replication inhibition. Development of such products has opened a new era in treatment of that chronic disorder. The new therapy is effective, convenient and is well tolerated by patients.
Daclatasvir was approved in the Russian Federation last June. The first batch of daclatasvir at R-Pharm in Russia is planned in H2, 2016.
An agreement signed between Bristol-Mayers Squibb and R-Pharm is implemented according to the objectives and priorities of the Strategy of development of the Russian pharmaceutical Industry Pharma-2020.
Manufacture of a new effective drug will be performed at the site of R-Pharm.